Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Gains from Sales and Divestitures: 2019-2022

Historic Gains from Sales and Divestitures for P3 Health Partners (PIII) over the last 4 years, with FY2022 value amounting to $5.0 million.

  • P3 Health Partners' Gains from Sales and Divestitures changed N/A to $5.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2022, which is N/A changed from last year.
  • P3 Health Partners' Gains from Sales and Divestitures amounted to $5.0 million in FY2022.
  • P3 Health Partners' 5-year Gains from Sales and Divestitures high stood at $5.0 million for FY2022, and its period low was $443750.0 during FY2020.
  • In the last 4 years, P3 Health Partners' Gains from Sales and Divestitures had a median value of $646875.0 in 2019 and averaged $1.7 million.
  • Within the past 5 years, the most significant YoY rise in P3 Health Partners' Gains from Sales and Divestitures was 2993.42% (2020), while the steepest drop was 2993.42% (2020).
  • P3 Health Partners' Gains from Sales and Divestitures (Annual) stood at $633333.0 in 2019, then decreased by 29.93% to $443750.0 in 2020, then soared by 48.83% to $660417.0 in 2021, then soared by 662.85% to $5.0 million in 2022.
  • Its Gains from Sales and Divestitures was $5.0 million in FY2022, compared to $660417.0 in FY2021 and $443750.0 in FY2020.